US › Healthcare

Obsidian Therapeutics, Inc. Common Stock (OBX)

US · Healthcare · Biotechnology

$17.50+2.04%

Last close · 2026-09-17

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-19.6M

EPS

$-1.19

EPS estimate

$-1.64

EPS came in at -1.19 against a street estimate of -1.64 — a beat of 27.2%.

Key statistics

Market cap

$1.06B

Forward P/E

0.0

P/B

0.00

Book value

$-13.10

EPS (TTM)

$-1.42

52-week high

$49.97

52-week low

$14.57

50-day MA

$20.62

200-day MA

$20.62

Beta

2.60

Analyst view

with an average price target of $42.50.

Shareholding

Insiders

0.81%

Institutions

27.36%

Recent filings & reports

Document	Date
Quarterly report · Q2 2026 OBSIDIAN THERAPEUTICS, INC. — 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company formed April 10, 2026; merger completed August 3, 2026 (s	2026-08-14
Results announced · Q3 2026 OBSIDIAN BIOPHARMACEUTICAL - COMPANY SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Net losses: $100.6 million (year ended December 31, 2025) and $	2026-08-03

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Obsidian Therapeutics, Inc. Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.